The global market for Dopamine Receptor Agonists was valued at US$ 786 million in the year 2024 and is projected to reach a revised size of US$ 1026 million by 2031, growing at a CAGR of 3.9% during the forecast period.

Dopamine Receptor Agonists Market

Dopamine receptor agonists are a class of drugs that mimic the action of dopamine by stimulating dopamine receptors in the brain. These medications are primarily used to treat neurological disorders such as Parkinson’s disease by compensating for the loss of dopamine-producing neurons. By activating dopamine receptors, they help improve motor control, reduce tremors, and alleviate symptoms associated with dopamine deficiency.

North American market for Dopamine Receptor Agonists is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Dopamine Receptor Agonists is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Dopamine Receptor Agonists in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Dopamine Receptor Agonists include Boehringer Ingelheim, Krka, Jingxin Pharma, Novartis, Qilu Pharma, Euro-Pharma, Torrent Pharmaceuticals, Teva, CSPC, Sun Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Dopamine Receptor Agonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dopamine Receptor Agonists.

The Dopamine Receptor Agonists market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dopamine Receptor Agonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Dopamine Receptor Agonists companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Dopamine Receptor Agonists Market Report

Report Metric	Details
Report Name	Dopamine Receptor Agonists Market
Accounted market size in year	US$ 786 million
Forecasted market size in 2031	US$ 1026 million
CAGR	3.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Pramipexole Piribedil Ropinirole Other
Segment by Application	Hospital Retail Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Boehringer Ingelheim, Krka, Jingxin Pharma, Novartis, Qilu Pharma, Euro-Pharma, Torrent Pharmaceuticals, Teva, CSPC, Sun Pharmaceutical, Les Laboratoires Servier, Desitin Arzneimittel, GlaxoSmithKline, Ruien Pharma, Kyowa Kirin, Huahai Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dopamine Receptor Agonists company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Dopamine Receptor Agonists Market growing?

Ans: The Dopamine Receptor Agonists Market witnessing a CAGR of 3.9% during the forecast period 2025-2031.

What is the Dopamine Receptor Agonists Market size in 2031?

Ans: The Dopamine Receptor Agonists Market size in 2031 will be US$ 1026 million.

Who are the main players in the Dopamine Receptor Agonists Market report?

Ans: The main players in the Dopamine Receptor Agonists Market are Boehringer Ingelheim, Krka, Jingxin Pharma, Novartis, Qilu Pharma, Euro-Pharma, Torrent Pharmaceuticals, Teva, CSPC, Sun Pharmaceutical, Les Laboratoires Servier, Desitin Arzneimittel, GlaxoSmithKline, Ruien Pharma, Kyowa Kirin, Huahai Pharma

What are the Application segmentation covered in the Dopamine Receptor Agonists Market report?

Ans: The Applications covered in the Dopamine Receptor Agonists Market report are Hospital, Retail Pharmacy, Other

What are the Type segmentation covered in the Dopamine Receptor Agonists Market report?

Ans: The Types covered in the Dopamine Receptor Agonists Market report are Pramipexole, Piribedil, Ropinirole, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Dopamine Receptor Agonists Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Pramipexole

1.2.3 Piribedil

1.2.4 Ropinirole

1.2.5 Other

1.3 Market by Application

1.3.1 Global Dopamine Receptor Agonists Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Dopamine Receptor Agonists Market Perspective (2020-2031)

2.2 Global Dopamine Receptor Agonists Growth Trends by Region

2.2.1 Global Dopamine Receptor Agonists Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Dopamine Receptor Agonists Historic Market Size by Region (2020-2025)

2.2.3 Dopamine Receptor Agonists Forecasted Market Size by Region (2026-2031)

2.3 Dopamine Receptor Agonists Market Dynamics

2.3.1 Dopamine Receptor Agonists Industry Trends

2.3.2 Dopamine Receptor Agonists Market Drivers

2.3.3 Dopamine Receptor Agonists Market Challenges

2.3.4 Dopamine Receptor Agonists Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Dopamine Receptor Agonists Players by Revenue

3.1.1 Global Top Dopamine Receptor Agonists Players by Revenue (2020-2025)

3.1.2 Global Dopamine Receptor Agonists Revenue Market Share by Players (2020-2025)

3.2 Global Top Dopamine Receptor Agonists Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Dopamine Receptor Agonists Revenue

3.4 Global Dopamine Receptor Agonists Market Concentration Ratio

3.4.1 Global Dopamine Receptor Agonists Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Dopamine Receptor Agonists Revenue in 2024

3.5 Global Key Players of Dopamine Receptor Agonists Head office and Area Served

3.6 Global Key Players of Dopamine Receptor Agonists, Product and Application

3.7 Global Key Players of Dopamine Receptor Agonists, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Dopamine Receptor Agonists Breakdown Data by Type

4.1 Global Dopamine Receptor Agonists Historic Market Size by Type (2020-2025)

4.2 Global Dopamine Receptor Agonists Forecasted Market Size by Type (2026-2031)

5 Dopamine Receptor Agonists Breakdown Data by Application

5.1 Global Dopamine Receptor Agonists Historic Market Size by Application (2020-2025)

5.2 Global Dopamine Receptor Agonists Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Dopamine Receptor Agonists Market Size (2020-2031)

6.2 North America Dopamine Receptor Agonists Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Dopamine Receptor Agonists Market Size by Country (2020-2025)

6.4 North America Dopamine Receptor Agonists Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Dopamine Receptor Agonists Market Size (2020-2031)

7.2 Europe Dopamine Receptor Agonists Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Dopamine Receptor Agonists Market Size by Country (2020-2025)

7.4 Europe Dopamine Receptor Agonists Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Dopamine Receptor Agonists Market Size (2020-2031)

8.2 Asia-Pacific Dopamine Receptor Agonists Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Dopamine Receptor Agonists Market Size by Region (2020-2025)

8.4 Asia-Pacific Dopamine Receptor Agonists Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Dopamine Receptor Agonists Market Size (2020-2031)

9.2 Latin America Dopamine Receptor Agonists Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Dopamine Receptor Agonists Market Size by Country (2020-2025)

9.4 Latin America Dopamine Receptor Agonists Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Dopamine Receptor Agonists Market Size (2020-2031)

10.2 Middle East & Africa Dopamine Receptor Agonists Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Dopamine Receptor Agonists Market Size by Country (2020-2025)

10.4 Middle East & Africa Dopamine Receptor Agonists Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Boehringer Ingelheim

11.1.1 Boehringer Ingelheim Company Details

11.1.2 Boehringer Ingelheim Business Overview

11.1.3 Boehringer Ingelheim Dopamine Receptor Agonists Introduction

11.1.4 Boehringer Ingelheim Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.1.5 Boehringer Ingelheim Recent Development

11.2 Krka

11.2.1 Krka Company Details

11.2.2 Krka Business Overview

11.2.3 Krka Dopamine Receptor Agonists Introduction

11.2.4 Krka Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.2.5 Krka Recent Development

11.3 Jingxin Pharma

11.3.1 Jingxin Pharma Company Details

11.3.2 Jingxin Pharma Business Overview

11.3.3 Jingxin Pharma Dopamine Receptor Agonists Introduction

11.3.4 Jingxin Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.3.5 Jingxin Pharma Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Dopamine Receptor Agonists Introduction

11.4.4 Novartis Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.4.5 Novartis Recent Development

11.5 Qilu Pharma

11.5.1 Qilu Pharma Company Details

11.5.2 Qilu Pharma Business Overview

11.5.3 Qilu Pharma Dopamine Receptor Agonists Introduction

11.5.4 Qilu Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.5.5 Qilu Pharma Recent Development

11.6 Euro-Pharma

11.6.1 Euro-Pharma Company Details

11.6.2 Euro-Pharma Business Overview

11.6.3 Euro-Pharma Dopamine Receptor Agonists Introduction

11.6.4 Euro-Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.6.5 Euro-Pharma Recent Development

11.7 Torrent Pharmaceuticals

11.7.1 Torrent Pharmaceuticals Company Details

11.7.2 Torrent Pharmaceuticals Business Overview

11.7.3 Torrent Pharmaceuticals Dopamine Receptor Agonists Introduction

11.7.4 Torrent Pharmaceuticals Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.7.5 Torrent Pharmaceuticals Recent Development

11.8 Teva

11.8.1 Teva Company Details

11.8.2 Teva Business Overview

11.8.3 Teva Dopamine Receptor Agonists Introduction

11.8.4 Teva Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.8.5 Teva Recent Development

11.9 CSPC

11.9.1 CSPC Company Details

11.9.2 CSPC Business Overview

11.9.3 CSPC Dopamine Receptor Agonists Introduction

11.9.4 CSPC Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.9.5 CSPC Recent Development

11.10 Sun Pharmaceutical

11.10.1 Sun Pharmaceutical Company Details

11.10.2 Sun Pharmaceutical Business Overview

11.10.3 Sun Pharmaceutical Dopamine Receptor Agonists Introduction

11.10.4 Sun Pharmaceutical Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.10.5 Sun Pharmaceutical Recent Development

11.11 Les Laboratoires Servier

11.11.1 Les Laboratoires Servier Company Details

11.11.2 Les Laboratoires Servier Business Overview

11.11.3 Les Laboratoires Servier Dopamine Receptor Agonists Introduction

11.11.4 Les Laboratoires Servier Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.11.5 Les Laboratoires Servier Recent Development

11.12 Desitin Arzneimittel

11.12.1 Desitin Arzneimittel Company Details

11.12.2 Desitin Arzneimittel Business Overview

11.12.3 Desitin Arzneimittel Dopamine Receptor Agonists Introduction

11.12.4 Desitin Arzneimittel Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.12.5 Desitin Arzneimittel Recent Development

11.13 GlaxoSmithKline

11.13.1 GlaxoSmithKline Company Details

11.13.2 GlaxoSmithKline Business Overview

11.13.3 GlaxoSmithKline Dopamine Receptor Agonists Introduction

11.13.4 GlaxoSmithKline Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.13.5 GlaxoSmithKline Recent Development

11.14 Ruien Pharma

11.14.1 Ruien Pharma Company Details

11.14.2 Ruien Pharma Business Overview

11.14.3 Ruien Pharma Dopamine Receptor Agonists Introduction

11.14.4 Ruien Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.14.5 Ruien Pharma Recent Development

11.15 Kyowa Kirin

11.15.1 Kyowa Kirin Company Details

11.15.2 Kyowa Kirin Business Overview

11.15.3 Kyowa Kirin Dopamine Receptor Agonists Introduction

11.15.4 Kyowa Kirin Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.15.5 Kyowa Kirin Recent Development

11.16 Huahai Pharma

11.16.1 Huahai Pharma Company Details

11.16.2 Huahai Pharma Business Overview

11.16.3 Huahai Pharma Dopamine Receptor Agonists Introduction

11.16.4 Huahai Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025)

11.16.5 Huahai Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Torrent Pharmaceuticals

TEVA

CSPC

Sun Pharmaceutical

Les Laboratoires Servier

List of Tables

Table 1. Global Dopamine Receptor Agonists Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Pramipexole

Table 3. Key Players of Piribedil

Table 4. Key Players of Ropinirole

Table 5. Key Players of Other

Table 6. Global Dopamine Receptor Agonists Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Dopamine Receptor Agonists Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Dopamine Receptor Agonists Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Dopamine Receptor Agonists Market Share by Region (2020-2025)

Table 10. Global Dopamine Receptor Agonists Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Dopamine Receptor Agonists Market Share by Region (2026-2031)

Table 12. Dopamine Receptor Agonists Market Trends

Table 13. Dopamine Receptor Agonists Market Drivers

Table 14. Dopamine Receptor Agonists Market Challenges

Table 15. Dopamine Receptor Agonists Market Restraints

Table 16. Global Dopamine Receptor Agonists Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Dopamine Receptor Agonists Market Share by Players (2020-2025)

Table 18. Global Top Dopamine Receptor Agonists Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dopamine Receptor Agonists as of 2024)

Table 19. Ranking of Global Top Dopamine Receptor Agonists Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Dopamine Receptor Agonists Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Dopamine Receptor Agonists, Headquarters and Area Served

Table 22. Global Key Players of Dopamine Receptor Agonists, Product and Application

Table 23. Global Key Players of Dopamine Receptor Agonists, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Dopamine Receptor Agonists Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Dopamine Receptor Agonists Revenue Market Share by Type (2020-2025)

Table 27. Global Dopamine Receptor Agonists Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Dopamine Receptor Agonists Revenue Market Share by Type (2026-2031)

Table 29. Global Dopamine Receptor Agonists Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Dopamine Receptor Agonists Revenue Market Share by Application (2020-2025)

Table 31. Global Dopamine Receptor Agonists Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Dopamine Receptor Agonists Revenue Market Share by Application (2026-2031)

Table 33. North America Dopamine Receptor Agonists Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Dopamine Receptor Agonists Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Dopamine Receptor Agonists Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Dopamine Receptor Agonists Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Dopamine Receptor Agonists Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Dopamine Receptor Agonists Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Dopamine Receptor Agonists Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Dopamine Receptor Agonists Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Dopamine Receptor Agonists Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Dopamine Receptor Agonists Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Dopamine Receptor Agonists Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Dopamine Receptor Agonists Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Dopamine Receptor Agonists Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Dopamine Receptor Agonists Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Dopamine Receptor Agonists Market Size by Country (2026-2031) & (US$ Million)

Table 48. Boehringer Ingelheim Company Details

Table 49. Boehringer Ingelheim Business Overview

Table 50. Boehringer Ingelheim Dopamine Receptor Agonists Product

Table 51. Boehringer Ingelheim Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 52. Boehringer Ingelheim Recent Development

Table 53. Krka Company Details

Table 54. Krka Business Overview

Table 55. Krka Dopamine Receptor Agonists Product

Table 56. Krka Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 57. Krka Recent Development

Table 58. Jingxin Pharma Company Details

Table 59. Jingxin Pharma Business Overview

Table 60. Jingxin Pharma Dopamine Receptor Agonists Product

Table 61. Jingxin Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 62. Jingxin Pharma Recent Development

Table 63. Novartis Company Details

Table 64. Novartis Business Overview

Table 65. Novartis Dopamine Receptor Agonists Product

Table 66. Novartis Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 67. Novartis Recent Development

Table 68. Qilu Pharma Company Details

Table 69. Qilu Pharma Business Overview

Table 70. Qilu Pharma Dopamine Receptor Agonists Product

Table 71. Qilu Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 72. Qilu Pharma Recent Development

Table 73. Euro-Pharma Company Details

Table 74. Euro-Pharma Business Overview

Table 75. Euro-Pharma Dopamine Receptor Agonists Product

Table 76. Euro-Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 77. Euro-Pharma Recent Development

Table 78. Torrent Pharmaceuticals Company Details

Table 79. Torrent Pharmaceuticals Business Overview

Table 80. Torrent Pharmaceuticals Dopamine Receptor Agonists Product

Table 81. Torrent Pharmaceuticals Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 82. Torrent Pharmaceuticals Recent Development

Table 83. Teva Company Details

Table 84. Teva Business Overview

Table 85. Teva Dopamine Receptor Agonists Product

Table 86. Teva Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 87. Teva Recent Development

Table 88. CSPC Company Details

Table 89. CSPC Business Overview

Table 90. CSPC Dopamine Receptor Agonists Product

Table 91. CSPC Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 92. CSPC Recent Development

Table 93. Sun Pharmaceutical Company Details

Table 94. Sun Pharmaceutical Business Overview

Table 95. Sun Pharmaceutical Dopamine Receptor Agonists Product

Table 96. Sun Pharmaceutical Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 97. Sun Pharmaceutical Recent Development

Table 98. Les Laboratoires Servier Company Details

Table 99. Les Laboratoires Servier Business Overview

Table 100. Les Laboratoires Servier Dopamine Receptor Agonists Product

Table 101. Les Laboratoires Servier Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 102. Les Laboratoires Servier Recent Development

Table 103. Desitin Arzneimittel Company Details

Table 104. Desitin Arzneimittel Business Overview

Table 105. Desitin Arzneimittel Dopamine Receptor Agonists Product

Table 106. Desitin Arzneimittel Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 107. Desitin Arzneimittel Recent Development

Table 108. GlaxoSmithKline Company Details

Table 109. GlaxoSmithKline Business Overview

Table 110. GlaxoSmithKline Dopamine Receptor Agonists Product

Table 111. GlaxoSmithKline Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 112. GlaxoSmithKline Recent Development

Table 113. Ruien Pharma Company Details

Table 114. Ruien Pharma Business Overview

Table 115. Ruien Pharma Dopamine Receptor Agonists Product

Table 116. Ruien Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 117. Ruien Pharma Recent Development

Table 118. Kyowa Kirin Company Details

Table 119. Kyowa Kirin Business Overview

Table 120. Kyowa Kirin Dopamine Receptor Agonists Product

Table 121. Kyowa Kirin Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 122. Kyowa Kirin Recent Development

Table 123. Huahai Pharma Company Details

Table 124. Huahai Pharma Business Overview

Table 125. Huahai Pharma Dopamine Receptor Agonists Product

Table 126. Huahai Pharma Revenue in Dopamine Receptor Agonists Business (2020-2025) & (US$ Million)

Table 127. Huahai Pharma Recent Development

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Dopamine Receptor Agonists Picture

Figure 2. Global Dopamine Receptor Agonists Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Dopamine Receptor Agonists Market Share by Type: 2024 VS 2031

Figure 4. Pramipexole Features

Figure 5. Piribedil Features

Figure 6. Ropinirole Features

Figure 7. Other Features

Figure 8. Global Dopamine Receptor Agonists Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Dopamine Receptor Agonists Market Share by Application: 2024 VS 2031

Figure 10. Hospital Case Studies

Figure 11. Retail Pharmacy Case Studies

Figure 12. Other Case Studies

Figure 13. Dopamine Receptor Agonists Report Years Considered

Figure 14. Global Dopamine Receptor Agonists Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Dopamine Receptor Agonists Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Dopamine Receptor Agonists Market Share by Region: 2024 VS 2031

Figure 17. Global Dopamine Receptor Agonists Market Share by Players in 2024

Figure 18. Global Dopamine Receptor Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Dopamine Receptor Agonists Revenue in 2024

Figure 20. North America Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Dopamine Receptor Agonists Market Share by Country (2020-2031)

Figure 22. United States Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Dopamine Receptor Agonists Market Share by Country (2020-2031)

Figure 26. Germany Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Dopamine Receptor Agonists Market Share by Region (2020-2031)

Figure 34. China Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Dopamine Receptor Agonists Market Share by Country (2020-2031)

Figure 42. Mexico Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Dopamine Receptor Agonists Market Share by Country (2020-2031)

Figure 46. Turkey Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Dopamine Receptor Agonists Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Boehringer Ingelheim Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 50. Krka Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 51. Jingxin Pharma Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 52. Novartis Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 53. Qilu Pharma Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 54. Euro-Pharma Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 55. Torrent Pharmaceuticals Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 56. Teva Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 57. CSPC Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 58. Sun Pharmaceutical Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 59. Les Laboratoires Servier Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 60. Desitin Arzneimittel Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 61. GlaxoSmithKline Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 62. Ruien Pharma Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 63. Kyowa Kirin Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 64. Huahai Pharma Revenue Growth Rate in Dopamine Receptor Agonists Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions